Skip to main content
. 2020 Feb 13;22(5):847–856. doi: 10.1111/dom.13970

Figure 2.

Figure 2

Mean (95% confidence intervals) of each clinical measure during treatment for propensity‐score matched individuals after intensification with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor or a sulphonylurea (SU) following metformin monotherapy. BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin